Tag: bladder cancer

The standard of care for T2-T4aN0M0 muscle-invasive bladder cancer (MIBC) and high-risk non-MIBC in fit patients is radical cystectomy (RC). In patients unfit for RC, or in cases where bladder preservation is desired, trimodality therapy (TMT) incorporating maximal transurethral resection of bladder tumor (TURBT) and radiation therapy (RT) with...
1. In this randomized controlled trial, time to recurrence was lower in patient with non-muscle-invasive urothelial cancer when treated with intravesical gemcitabine as compared to saline controls. 2. There was no difference in all-cause mortality between the two treatment groups. Evidence Rating: 1 (Excellent) Study Rundown: Non-muscle-invasive urothelial cancer is the most...
1. This study demonstrated no significant association between the risk of bladder cancer and either pioglitazone use or duration of pioglitazone therapy. 2. While there was no association between pioglitazone use and non-Hodgkin lymphoma, melanoma, breast cancer, lung cancer, endometrial cancer, colon cancer, rectal cancer, or kidney cancer in this...
1.Diffusion-weighted magnetic resonance imaging (DWMRI)  was shown to be both sensitive and specific for identification of pelvic lymph node metastases among patients with prostate or bladder cancer.  2. The inclusion of several additional imaging criteria in conjunction with DWMRI reduced the number of diagnostic errors and was associated with superior...
1. Concomitant seminal vesicle invasion (cSVI) in patients with urothelial carcinoma of the bladder (UCB) and prostatic stromal infiltration was associated with decreased cancer-specific and overall survival rates. 2. Incorporation of cSVI into multivariate analysis increased accuracy in predicting mortality events.  Evidence Rating Level: 2 (Good) Study Rundown: In its link to...